Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AUPH with free AI briefings, catalyst countdowns, and dilution alerts.

AUPH · Aurinia Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$486.5M Cash on Hand
CF+ Cash Runway
Follow AUPH by email Get an email when AUPH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AUPH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Voclosporin
FDA approved Jan 2021 · Lupkynis
Lupus Nephritis Phase 4 · NCT07611214 Recruiting
mycophenolic acid analog (MPAA) Lupus Nephritis Phase 4 · NCT07611214 Recruiting
Corticosteroid Lupus Nephritis Phase 4 · NCT07611214 Recruiting
0.10% VOS Dry Eye Syndrome Phase 2/3 · NCT04147650 Completed
Cyclosporine Psoriasis Phase 3 · NCT00408187 Completed
0.20% VOS Dry Eye Syndrome Phase 2/3 · NCT04147650 Completed
0.05% Voclosporin Ophthalmic Solution (VOS) Dry Eye Syndrome Phase 2/3 · NCT04147650 Completed
Aritinercept Myasthenia Gravis, Generalized Phase 1/2 · NCT07596901 Recruiting
Voclosporin Ophthalmic Solution Dry Eye Phase 2 · NCT03597139 Completed

Also used in these trials (approved or third-party drugs, not AUPH's own candidates): Belimumab, Tacrolimus Extended-Release, Simvastatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AUPH holds $486.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUPH files for a raise →

👥 Who Owns AUPH

Insiders 12.8% Other 5%+ holders 9.7% Institutions (382 holders) 61% Public and other holders 16.5%
HolderTypeShares% of sharesAs of
Kevin Tang
Chief Executive Officer, Director, 10% o · +10,000 options
Insider 13,044,106 9.73% 2026-05-29
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13D) 13,044,106 9.73% 2026-06-02
Peter Greenleaf
Chief Executive Officer, Director · +772,397 options
Insider 1,840,379 1.37% 2026-02-27
Matthew Maxwell Donley
Chief Operating Officer · +97,256 options
Insider 680,299 0.51% 2026-02-27
Stephen P. Robertson
Chief Legal Officer · +98,813 options
Insider 576,981 0.43% 2026-11-13
Joseph M Miller
Chief Financial Officer · +95,700 options
Insider 576,421 0.43% 2026-02-27
Greg Keenan
SVP, Chief Medical Officer · +67,870 options
Insider 154,449 0.12% 2026-03-06
Ryan Cole
Chief Operating Officer · +70,230 options
Insider 116,144 0.09% 2026-05-18
Michael S Hearne
Chief Financial Officer · +70,230 options
Insider 116,144 0.09% 2026-05-18
Jeffrey Allen Bailey
Director · +61,416 options
Insider 22,775 0.02% 2025-11-21
Craig A Johnson
Director · +61,416 options
Insider 14,592 0.01% 2025-11-21

Share count 133,998,660 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AUPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.